Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: A randomized, controlled study in infants in the Republic of Korea

Vaccine

Volumn 29, Issue 8, 2011, Pages 1551-1557

  Lee, Soo Young ^a   Hwang, Hui Sung ^a   Kim, Jong Hyun ^b   Kim, Hyun Hee ^c   Lee, Hyun Seung ^d   Chung, Eun Hee ^e   Park, Su Eun ^f   Ma, Sang Hyuk ^g   Chang, Jin Keun ^h   Guitton, Fabrice ⁱ   Ortiz, Esteban ⁱ   Kangj, Jin Han ^j  

^a Bupyeong gu   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d The Catholic University of Korea   (South Korea)

^e Dankook University   (South Korea)

^f Pusan National University Hospital   (South Korea)

^g Changwon Fatima Hospital   (South Korea)

^h Hanil Medical Center   (South Korea)

ⁱ SANOFI PASTEUR   (France)

^j The Catholic University of Korea   (South Korea)

more..

Author keywords

Combined; Diphtheria Tetanus acellular pertussis; Inactivated; Poliovirus vaccine; Vaccines

Indexed keywords

BACTERIAL VACCINE; DIPHTHERIA ANTIBODY; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS ACCELULAR PERTUSSIS PLUS INACTIVATED POLIOVIRUS VACCINE; HEMAGGLUTININ; TETRAXIM; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANOREXIA; ANTIBODY TITER; ARTICLE; ATOPIC DERMATITIS; BRONCHIOLITIS; BRONCHITIS; CLINICAL ASSESSMENT; CONTROLLED STUDY; CRYING; DIAPER DERMATITIS; DIARRHEA; DROWSINESS; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEVER; GASTROENTERITIS; HUMAN; IMMUNOGENICITY; INFANT; INJECTION SITE REACTION; IRRITABILITY; KOREA; MAJOR CLINICAL STUDY; PHARYNGITIS; POLIOMYELITIS VIRUS; POLIOMYELITIS VIRUS 1; POLIOMYELITIS VIRUS 2; POLIOMYELITIS VIRUS 3; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHINITIS; RHINOPHARYNGITIS; SEROCONVERSION; SIDE EFFECT; SWELLING; TENDERNESS; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

EID: 79952701968     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.12.094     Document Type: Article

References (33)

1. Armstrong EP. Economic benefits and cost sassociated with targetvaccinations. J Manag Care Pharm 2007;7(Suppl B):S12-5.
2. Ehreth J. The global value of vaccination. Vaccine 2003;21:596-600.
3. Edwards KM, Decker M. Pertussis vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 5th ed. Philadelphia, PA: Saunders; 2008. p. 467-517.
4. Cutts FT. Advances and challenges for the expanded programme on immunization. Br Med Bull 1998;54:445-61.
5. Plotkin SA. Vaccines: past, present and future. Nat Med 2005;11(Suppl 4):S5-11.
6. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 2000;13:302-17.
7. Decker MD. Principles of pediatric combination vaccines and practical issues related to use in clinical practice. Pediatr Infect Dis J 2001;20(11Suppl):S10-8.
8. Kalies H, Grote V, Verstraeten T, Hessel L, Schmitt HJ, von Kries R. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J 2006;25:507-12.
9. Dodd D. Benefits of combination vaccines: effective vaccination on a simplified schedule. Am J Manag Care 2003;9(Suppl 1):S6-12.
10. WHO Vaccine Preventable Diseases Monitoring System 2009 Global Summary; Cited Jan 2010. Available from: http://www.who.int/vaccines/globalsummary/immunization/countryprofileselect.cfm [accessed 24.01.10].
11. Shin T, Kim C-B, Ahn Y-H, Kim H-Y, Cha BH, Uh Y, et al. The comparative evaluation of expanded national immunization policies in Korea using an analytic hierarchy process. Vaccine 2009;27:792-802.
12. Simondon F, Yam A, Gagnepain JY, Wassilak S, Danve B, Cadoz M. Comparative safety and immunogenicity of an acellular versus whole-cell pertussis component of diphtheria-tetanus-pertussis vaccines in Senegalese infants. Eur J Clin Microbiol Infect Dis 1996;15:927-32.
13. Simondon F, Preziosi MP, Yam A,Kane CT, Chabirand L,Iteman I, etal. Randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine 1997;15:1606-12.
14. Vidor E, Meschievitz C, Plotkin S. Fifteen years of experience with Vero-produced enhanced potency inactivated poliovirus vaccine. Pediatr Infect Dis J 1997;16:312-22.
15. Lagos R, Kotloff KL, Hoffenbach A, San Martin O, Abrego P, Ureta AM, et al. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six month-old Chile an infants. Pediatr Infect Dis J 1998;17:294-304.
16. Carlsson RM, Claesson BA, Selstam U, Fagerlund E, Granstrom M, Blondeau C, et al. Safety and immunogenicity of a combined diphtheria, tetanus, acellu-lar pertussis, inactivated polio vaccine Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age. Pediatr Infect Dis J 1998;17:1026-33.
17. Mallet E, Fabre P, Pines E, Salomon H, Staub T, Schödel F, et al. Immunogenicity and safety of a new liquid hexavalent combined vaccine compared with separate administration of reference licensed vaccines in infants. Pediatr Infect Dis J 2000;19:1119-27.
18. Kanra G, Selier T, Yurdakök K, Yavuz T, Baskan S, Ulukol B, et al. Immuno-gencity study of a combined diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis vaccine used to reconstitute a freeze-dried Haemophilus influen-zae type b vaccine (DTacP-IPV//PRP-T) administered simultaneously with a hepatitis B vaccine at two, three and four months of life. Vaccine 2000;18:947-54.
19. Capeding RM, Cadorna-Carlos J, Book-Montellano M, Ortiz E. Immunogenicity and safety of a DTaP-IPV//PRP-T combination vaccine at 6, 10, 14 weeks of age (EPI schedule) and concomitant Hepatitis B vaccination at birth, 6, 14 or 6, 10, 14 weeks of age. WHO Bull 2008;86:443-51.
20. TM) at 6, 10, 14 weeks of age. Indian Pediatr 2009;46:975-82.
21. Carlsson RM, Claesson BA, Fagerlund UE, Knutsson N, Laudin C. Antibodypersis-tence infive-year old children who received a pentavalent combination vaccine in infancy. Pediatr Infect Dis J 2002;21:1535-41.
22. Vidor E, Plotkin SA. Immunogenicity of a two-component (PT & FHA) acel-lular pertussis vaccine in various combinations. Hum Vaccin 2008;4:328-40.
23. Plotkin SA. Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J 2001;20:63-75.
24. Mallet E, Hoffenbach A, Salomon H, Blondeau C, Fritzell B. Primary immunization with combined, acellular DTaP-IPV-Act-HIB vaccine given at 2-3-4 or 2-4-6 months of age. In: The 14th European Societies for Paediatric Infectious Diseases. 1996.
25. Kim JS, Hong YJ, Kim JD, Jang YT, Kang JH. Immunogenicity and safety of enhanced-inactivated poliovaccine (eIPV) in healthy Korean infants. Korean J Pediatr 2006;49:864-9.
26. Gustafsson L, Hessel L, Storsaeter J, Olin P. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatrics 2006;8:978-84.
27. Swedish Institute for Infectious Disease Control. Pertussis surveillance in Sweden with enhanced follow-up of cohorts immunized with acel-lular pertussis vaccines 2006 Appendix 2 SP-MSD. Available from: http://www.smittskyddsinstitutet.se/upload/Publikationer/11-y-report-app202-SPMSD.pdf [accessed 12.03.10].
28. Hessel L, Mast CH, Teyssou R. Effectiveness of the 2-component acellular pertussis combination vaccine 5 years experience of routine practice in Sweden. Int J Infect Dis 2004;8(Suppl 1):S75 [abstract 18.023].
29. Olin P, Hallander HO. Marked decline in pertussis followed reintroduction of pertussis vaccination in Sweden. Euro Surveill 1999;4:128-9.
30. Nilsson L, Rydevik G. Eleven Year Report: Pertussis surveillance in Sweden Progress Report October 1, 1997-December 31, 2008 with an executive summary. Available from: http://www.smittskyddsinstitutet.se/upload/Publikationer/smirapport-06-2009.pdf [accessed 12.03.10].
31. Cherry JD, Brunell Ph A, Golden GS, Karzon DT. Report of the task force on pertussis and pertussis immunization-1988. Pediatrics 1988;81:933-84.
32. Decker MD, Edwards KM, Steinhoff MC, Rennels MB, Pichichero ME, Englund JA, et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics 1995;96:557-66.
33. Englund JA, Decker MD, Edwards KM, Pichichero ME, Steinhoff MC, Anderson EL. Acellular and whole-cell pertussis vaccines as booster doses: a multicenter study. Pediatrics 1994;93:37-43.